Olaparib, PARP1 inhibitor in ovarian cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Olaparib, PARP1 inhibitor in ovarian cancer

Published:2012-07-13 Issue:10 Volume:21 Page:1575-1584
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Marchetti Claudia,Imperiale Ludovica,Gasparri Maria Luisa,Palaia Innocenza,Pignata Sandro,Boni Terenzio,Bellati Filippo,Benedetti Panici Pierluigi

Publisher

Informa Healthcare

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.1517/13543784.2012.707189

Reference40 articles.

1. Global cancer statistics

2. New therapies for ovarian cancer: Cytotoxics and molecularly targeted agents

3. Carcinoma of the Ovary

4. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm

5. DNA strand breakage, activation of poly (ADP-ribose) synthetase, and cellular energy depletion are involved in the cytotoxicity of macrophages and smooth muscle cells exposed to peroxynitrite.

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ThermoTargetMiner as a proteome integral solubility alteration target database for prospective drugs against lung cancer;2024-08-06

2. Niraparib for the treatment of metastatic ccRCC in a patient with CDK12 and RAD51C mutations: a case report;Frontiers in Pharmacology;2024-06-17

3. Clinical significance of the CD98hc-CD147 complex in ovarian cancer: a bioinformatics analysis;Journal of Obstetrics and Gynaecology;2023-03-17

4. Incidence and risk of hypertension associated with PARP inhibitors in cancer patients: a systematic review and meta-analysis;BMC Cancer;2023-01-31

5. Diverse genetic spectrum among patients who met the criteria of hereditary breast, ovarian and pancreatic cancer syndrome;Journal of Gynecologic Oncology;2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3